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ABSTRACT
Objective The bacterial intestinal microbiota plays
major roles in human physiology and IBDs. Although
some data suggest a role of the fungal microbiota in IBD
pathogenesis, the available data are scarce. The aim of
our study was to characterise the faecal fungal
microbiota in patients with IBD.
Design Bacterial and fungal composition of the faecal
microbiota of 235 patients with IBD and 38 healthy
subjects (HS) was determined using 16S and ITS2
sequencing, respectively. The obtained sequences were
analysed using the Qiime pipeline to assess composition
and diversity. Bacterial and fungal taxa associated with
clinical parameters were identiﬁed using multivariate
association with linear models. Correlation between
bacterial and fungal microbiota was investigated using
Spearman’s test and distance correlation.
Results We observed that fungal microbiota is skewed
in IBD, with an increased Basidiomycota/Ascomycota
ratio, a decreased proportion of Saccharomyces
cerevisiae and an increased proportion of Candida
albicans compared with HS. We also identiﬁed disease-
speciﬁc alterations in diversity, indicating that a Crohn’s
disease-speciﬁc gut environment may favour fungi at the
expense of bacteria. The concomitant analysis of
bacterial and fungal microbiota showed a dense and
homogenous correlation network in HS but a
dramatically unbalanced network in IBD, suggesting the
existence of disease-speciﬁc inter-kingdom alterations.
Conclusions Besides bacterial dysbiosis, our study
identiﬁes a distinct fungal microbiota dysbiosis in IBD
characterised by alterations in biodiversity and
composition. Moreover, we unravel here disease-speciﬁc
inter-kingdom network alterations in IBD, suggesting
that, beyond bacteria, fungi might also play a role in IBD
pathogenesis.
INTRODUCTION
Crohn’s disease (CD) and UC, the two primary
types of IBD, are lifelong conditions that usually
affect young subjects and substantially alter their
quality of life. The exact pathogenesis of IBD
remains unknown; however, studies over the last
decade have demonstrated that IBD involves an
altered immune response towards gut microbiota in
genetically predisposed subjects and under the
inﬂuence of environmental factors. The bacterial
microbiota in IBD has been thoroughly investi-
gated, and several groups worldwide observed a
bacterial dysbiosis (an imbalance in composition)
that is characterised by a reduced biodiversity, a
decrease in some bacteria belonging to the
Firmicutes phylum (such as Faecalibacterium praus-
nitzii) and an increase in bacteria belonging to the
Proteobacteria phylum such as Escherichia coli.1–5
However, other microorganism types colonising
the human gut have not been thoroughly investi-
gated. With the exception of a recent study high-
lighting the possible role of the enteric virome in
IBD,6 the data are scarce, particularly regarding
fungal microbiota. Fungi have long been suspected
in IBD pathogenesis. Many years ago, antibodies
directed against Saccharomyces cerevisiae mannan
(Anti Saccharomyces cerevisiae antibody (ASCA))
were shown to be associated with CD. Moreover,
several IBD-associated genes, such as Card9, are
involved in immune responses to fungi.7 In mice,
gut inﬂammation promotes fungi proliferation;8
conversely, some fungi can modulate susceptibility
Signiﬁcance of this study
What is already known on this subject?
▸ The bacterial intestinal microbiota is
unbalanced in IBDs and plays a role in its
pathogenesis.
▸ The fungal microbiota has been poorly studied
despite several clues of its role in IBD
pathogenesis.
▸ Card9 and Dectin1, two key molecules involved
in the innate immunity against fungi, strongly
inﬂuence mice susceptibility to intestinal
inﬂammation and the fungal microbiota.
What are the new ﬁndings?
▸ The faecal fungal microbiota is imbalanced in
patients with IBD.
▸ The concomitant analysis of the bacterial
microbiota in the same subjects showed many
correlations between bacterial and fungal
components with differences between IBD and
healthy subjects, suggesting the existence of
disease-speciﬁc inter-kingdom alterations.
How might it impact on clinical practice in
the foreseeable future?
▸ These results support the role of fungal
microbiota in IBD pathogenesis and indicate a
new potential therapeutic target.
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to inﬂammation in a negative (Candida albicans) or positive
(Saccharomyces boulardii) manner.8–11 Finally, mice lacking
major genes involved in fungi sensing, such as Dectin-1 or
Card9, have an increased fungal microbiota load and are more
susceptible to colitis.12 13 These data suggest a link between
fungal microbiota and IBD pathogenesis.
Here, we characterised the fungal microbiota in both healthy
subjects (HS) and patients with well-phenotyped IBD using
high-throughput sequencing technology. In the corresponding
patients, we also determined the bacterial microbiota compos-
ition and the sequence of 22 single-nucleotide polymorphisms
(SNPs) in genes known to be involved in fungal susceptibility.
We observed a clear fungal dysbiosis in patients with IBD.
Moreover, a correlation analysis suggested altered inter-kingdom
relations in IBD. Finally, while somewhat lacking in power, our
genotype–fungal microbiota analysis suggested that genes may
be a driving factor of the fungal microbiota dysbiosis in IBD.
Overall, the data presented in this study represent the most
comprehensive analysis of fungal microbiota in patients with
IBD to date and provide a rationale to support the role of
fungal microbiota in IBD pathogenesis. These data thus pave the
way for intervention studies targeting fungal microbiota.
RESULTS
Bacterial dysbiosis in IBD
Our study population was composed of 235 patients with well-
phenotyped IBD and 38 HS (see online supplementary 1). We
ﬁrst analysed the bacterial fraction of the microbiota using 16S
sequencing. A beta diversity analysis showed a clustering of
samples according to disease phenotypes (ﬁgure 1A, B, online
supplementary ﬁgure S1). Compared with HS samples, the
alpha diversity (assessed using four different indexes) was sig-
niﬁcantly decreased in UC and CD and particularly in samples
from patients in ﬂare (ﬁgure 1C, D, online supplementary ﬁgure
S2). In all phenotypes, the bacterial microbiota was dominated
by bacteria from Firmicutes, Bacteroidetes and Proteobacteria
phyla (ﬁgure1E, F, online supplementary ﬁgure S3). These data
are in accordance with the published literature and validate the
quality of our cohort and the methods used.
Altered fungal microbiota diversity in IBD
Using ITS2 sequencing, we then assessed the composition of the
fungal microbiota in our population. The clustering between the
samples according to disease phenotype was weaker than with
bacterial microbiota (ﬁgure 2A, B, online supplementary ﬁgure
S4A). Notably, no statistically signiﬁcant difference was observed
between samples from patients with CD and UC or between
samples from patients with IBD in remission and HS. However,
a difference was observed between samples from patients with
IBD in ﬂare and HS (p=0.0008) or patients with IBD in remis-
sion (p=0.0007). This fungal microbiota-speciﬁc signal in ﬂare
was observed with a higher intensity in UC (p=0.0002) than in
CD (p=0.006; see online supplementary ﬁgure S4B-C). Similar
to the results found with the bacterial microbiota, the alpha
diversity of the fungal microbiota was decreased in patients with
IBD (ﬁgure 2C, online supplementary ﬁgure S5A–D). This
feature was primarily found in samples from patients with UC,
whereas fungi diversity was largely similar among the HS and
patients with CD. To explore the equilibrium between bacteria
and fungi diversity in the gut, we then determined the
fungi-to-bacteria diversity ratio. This ratio was increased in IBD
samples and particularly in CD and ﬂares (ﬁgure 2D, online sup-
plementary ﬁgure S5E–G). The highest ratio was found among
patients with CD and demonstrated ileal involvement. In both
HS and patients with IBD, the fungal microbiota was dominated
by fungi from the Ascomycota and Basidiomycota phyla with
some variations according to disease phenotype (ﬁgure 2E, F,
online supplementary ﬁgure S6). Among the most dominant
genera were Saccharomyces, Debaryomyces, Penicillium,
Kluyveromyces and Candida. Interestingly, Saccharomyces,
Debaryomyces and Kluyveromyces are found in food (cheese,
bread, beer notably); they might be routinely ingested in this
French cohort, suggesting a possible inﬂuence of the diet habits,
although a speciﬁc study is needed to explore this hypothesis.
These data show speciﬁc alterations in fungal microbiota
diversity in parallel with modiﬁcations of the bacterial micro-
biota. Taken together, this suggests that the environmental
changes during inﬂammation might affect differently fungi and
bacteria and induce an altered fungal–bacterial inter-kingdom
relationship in IBD.
Distortion in bacterial and fungal microbiota composition in
IBD
We identiﬁed the microbial features associated with disease
phenotype and used a multivariate association test to control for
the effects of potential confounding factors such as age, gender,
smoking and treatment (multivariate association with linear
models (MaAsLin); see ‘Materials and methods’ for details).
Regarding bacterial microbiota, we observed an alteration in the
abundance of several taxa in IBD compared with HS, in ﬂare
compared with remission and in IBD with ileal involvement
compared with IBD without ileal involvement (ﬁgure 3A; see
online supplementary ﬁgures S7A and 8, table S1 for full
MaAsLin output). Many of these taxa have been reported in pre-
vious studies,1 5 including Ruminococcaceae, Lachnospiraceae,
Enterobacteriaceae, Pasteurellaceae, Rikenellaceae and
Gemellaceae. Notably, Ruminococcus, Coprococcus, Blautia,
Eubacterium and Dorea abundance were decreased in IBD,
Roseburia, Faecalibacterium, Dorea and Blautia abundance were
decreased in IBD ﬂare and Ruminococcus gnavus was increased
in ileal CD. In addition to conﬁrming these already demon-
strated associations, we also found new associations such as a
decrease in Anaerostipes in IBD and particularly in ﬂare and in
ileal CD. We also found an increase of Streptococcus anginosus
in IBD and an increase of Aggregatibacter segnis and
Actinobacillus (two members of the Pasteurellaceae family) in
IBD ﬂare compared with remission.
When analysing fungal microbiota, we identiﬁed a lower
number of associations with the disease phenotype (ﬁgure 3B;
see online supplementary ﬁgure S7B, table S2 for full MaAsLin
output). One of the most striking features was the increased
abundance of Basidiomycota in IBD and particularly in ﬂare,
which was balanced by an equivalent decrease in Ascomycota.
Among the decreased Ascomycota in IBD and in ﬂare,Malassezia
sympodialis was identiﬁed. However, the Saccharomyces genus
and particularly S. cerevisiae species exhibited the strongest
signals. We thus performed real-time qPCR targeting S. cerevisiae
on the same samples and conﬁrmed a clear decrease in S. cerevi-
siae both in the absolute number and regarding the proportion in
IBD and particularly in ﬂare (ﬁgure 3C, online supplementary
ﬁgure S9A-B). Although C. albicans abundance is increased in
CD,14 Candida was not identiﬁed to be associated with disease
phenotype in the multivariate analysis. We thus performed real-
time qPCR targeting C. albicans on the same samples to speciﬁc-
ally examine this microorganism. The C. albicans proportion and
absolute number were signiﬁcantly increased in IBD ﬂare com-
pared with IBD in remission (ﬁgure 3D, E, online supplementary
ﬁgure S9C). We investigated correlations between their respective
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abundance. Basidiomycota and Ascomycota abundances
exhibited a strong negative correlation with each other
(see online supplementary ﬁgure S9D). Moreover, the
Basidiomycota-to-Ascomycota abundance ratio was dramatically
different according to the disease phenotype with higher values
in IBD ﬂare compared with IBD in remission and HS
(ﬁgure 3F-G), suggesting that this ratio could represent a fungal
dysbiosis index.
S. cerevisiae induces a regulatory response of dendritic cells
Due to the sequencing and qPCR results, we hypothesised that
S. cerevisiae and C. albicans could respectively exert a protective
and worsening role in the inﬂammatory process. As a proof of
principle, we assessed the interleukin (IL)6 and IL10 production
of murine bone marrow-derived dendritic cells (BMDCs) after
stimulation with the two heat-killed yeast strains. The IL6 pro-
duction was similar among S. cerevisiae and C. albicans;
however, the production of the anti-inﬂammatory cytokine IL10
was signiﬁcantly higher following stimulation with S. cerevisiae,
suggesting an anti-inﬂammatory effect of S. cerevisiae compared
with C. albicans (ﬁgure 4). Interestingly, the observed effects
were Card9-dependent because cytokine production was nearly
abolished in DC from Card9 KO mice. This conﬁrmed the
central role of this gene in host–fungi interactions.
IBD microbiota show-speciﬁc bacteria–fungi associations
We next assessed whether the fungi microbiota composition was
correlated with the bacterial composition. To address this, we
Figure 1 Altered bacterial microbiota biodiversity and composition in IBD. (A and B) Beta diversity. Principal coordinate analysis of Bray–Curtis
distance with each sample coloured according to the disease phenotype. PC1, PC2 and PC3 represent the top three principal coordinates that
captured most of the diversity. The fraction of diversity captured by the coordinate is given as a percentage. Groups were compared using
Permanova method. (C and D) Observed species number describing the alpha diversity of the bacterial microbiota in the various groups studied
(Kruskal–Wallis test with Dunn’s multiple comparison test). (E and F) Global composition of bacterial microbiota at the phyla and family levels.
Healthy subjects (HS) and patient subgroups are labelled on the x-axis and expressed as the relative operational taxonomic unit (OTUs) abundance
for each group. In all panels: *p<0.05; **p<0.01; ***p<0.001. CD, Crohn’s disease.
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investigated a correlation at the genus level according to disease
phenotype. We observed a disease-speciﬁc pattern with a higher
number of signiﬁcant correlations in UC compared with HS
(ﬁgure 5). Although the number of correlations was similar in
HS and in CD, the strength of the correlations was weaker in
CD (ﬁgure 5).
Interestingly, in patients with IBD, there was a positive correl-
ation between the abundance of Saccharomyces and the abun-
dance of several bacteria that display reduced abundance in IBD
such as Biﬁdobacterium, Blautia, Roseburia and Ruminococcus.
On the other hand, unidentiﬁed Malasseziales followed an
opposite pattern. Then, to demonstrate the global intra-
kingdom and inter-kingdom equilibrium according to disease
phenotype, we built correlation networks at the genus level
involving both bacteria and fungi (ﬁgure 6). In HS, the bacterial
and fungi diversity was high (ﬁgures 1 and 2), with a network
showing no marked foci of attractions with both positive and
negative correlations distributed throughout the nodes.
Strikingly, the CD and UC networks were dramatically different.
Notably, many negative correlations connecting genera from the
Proteobacteria phylum to members of the Firmicutes phylum
were observed in IBD. Involvement of fungi genera from the
Basidiomycota phylum, and particularly unidentiﬁed
Malasseziales, in correlations was decreased in CD but increased
Figure 2 Altered fungal microbiota biodiversity and composition in IBD. (A and B) Beta diversity. Principal coordinate analysis of Bray–Curtis
distance with each sample coloured according to the disease phenotype. PC1, PC2 and PC3 represent the top three principal coordinates that
captured most of the diversity. The fraction of diversity captured by the coordinate is given as a percentage. Groups were compared using
Permanova method. (C) Observed species number describing the alpha diversity of the fungal microbiota in the various groups studied. (D) ITS2/16S
observed species ratio (Kruskal–Wallis test with Dunn’s multiple comparison test. (E and F) Global composition of fungal microbiota at the phyla
and genus levels. Healthy subjects (HS) and patient subgroups are labelled on the x-axis and expressed as relative OTUs abundance for each group.
In all panels: *p<0.05; **p<0.01; ***p<0.001. CD, Crohn’s disease.
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in UC compared with HS. Similar results were obtained when
Spearman’s test was used to build the correlation network (data
not shown).
Taken together, these results suggest a complex relationship
between the bacteria and fungi in the gut microbiota and that
speciﬁc alterations are present in CD and UC.
Fungal microbiota–genotype association
In mice, the gut bacterial microbiota has been shown to be inﬂu-
enced by host genes.15 16 Substantial data suggest similar effects
in humans.17 18 However, no data are available regarding fungal
microbiota. We thus tested for a correlation between the relative
abundance of fungal taxa associated with the disease phenotype
(Basidiomycota and Ascomycota phyla as well as S. cerevisiae
and M. sympodialis species) and the Card9 SNPs associated
with IBD as well as several other SNPs that have been involved
in defective responses to fungi.12 19–23 We used standard linear
regression and adjusted all analyses for age, gender, smoking
and treatment. With a total of 84 tests, the Bonferroni corrected
p value threshold for an initial alpha of 5% was 6×10−4. As
shown in table 1, which presents the 10 most signiﬁcant associa-
tions, no test passed that threshold. Such a stringent signiﬁcance
threshold led to only limited power for our population. For
example, we had 80% power to detect SNP explaining 10% (or
more) of the variance of the tested taxa, but <2% power to
detect SNP explaining 1% of the variance. While the presence
of taxa-associated SNPs and the magnitude of the SNP effect
remain to be determined, large effect size (eg, ≥10%) appear
unlikely in regard of the marginal effect of these SNPs on IBD.
However, we identiﬁed interesting trends: notably, a Dectin1
SNP associated with medically refractory UC (rs2078178, ‘T’
allele12) was negatively correlated with the abundance of M.
sympodialis (itself decreased in IBD ﬂare). In the same manner,
the IBD-associated CARD9 SNP (rs10781499, ‘A’ allele21) was
negatively correlated with the abundance of S. cerevisiae (itself
decreased in IBD).
Figure 3 Bacterial and fungal taxa
associated with IBD. (A and B)
Differences in abundance are shown
for the bacterial and fungal taxa
detected using a multivariate statistical
approach (see ‘Material and
Methods’). The fold change for each
taxon was calculated by dividing the
mean abundance in the cases by that
of the controls. The number of subjects
that have any presence (>0) of the
indicated taxon is indicated in
brackets, and taxon with a mean
abundance of >0.5% in at least one of
the groups is indicated with ‘#’. (C)
Absolute Saccharomyces cerevisiae
abundance in the faecal microbiota
quantiﬁed using qRT-PCR (mean
±SEM). (D) Relative proportion of
Candida albicans calculated by
subtracting the log number of C.
albicans from the log number of all
fungi. (E) Absolute C. albicans
abundance in the faecal microbiota
quantiﬁed using qRT-PCR (mean
±SEM). (F) Basidiomycota/Ascomycota
relative abundance ratio in the various
groups studied (Kruskal–Wallis test
with Dunn’s multiple comparison test,
*p<0.05; **p<0.01; ***p<0.001;
****p<0.0001). CD, Crohn’s disease;
HS, healthy subjects.
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DISCUSSION
In this study, we showed that disease-speciﬁc changes in the
fungal gut microbiota are present in IBD. The simultaneous
analysis of both the fungal and the bacterial microbiota enabled
the elucidation of differences in the inter-kingdom equilibrium
between patients with IBD and HS.
Figure 4 Saccharomyces cerevisiae and Candida albicans induces distinct dendritic cell response. Interleukin (IL)10 (A) and IL6 (B) secretion by
mouse bone marrow-derived dendritic cells following stimulation with S. cerevisiae and C. albicans (mean±SEM). The numbers of mice per
experiment are n=5–15 (Mann–Whitney U test). KO, knockout; WT, wildtype.
Figure 5 Speciﬁc bacteria–fungi
correlation pattern in IBD. Distance
correlation plots of the relative
abundance of fungi and bacteria
genera. Healthy subjects (HS) (left), UC
(middle) and Crohn’s disease (CD)
(right). Statistical signiﬁcance was
determined for all pairwise
comparisons; only signiﬁcant
correlations (p value <0.05 after false
discovery rate correction) are displayed.
Positive values (blue squares) indicate
positive correlations, and negative
values (red squares) indicate inverse
correlations. The shading of the square
indicates the magnitude of the
association; darker shades are more
strongly associated than lighter
shades. The sign of the correlation was
determined using Spearman’s method.
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Bacterial biodiversity was decreased in both CD and UC.
However, fungal biodiversity was decreased only in UC. For
CD, this suggests that CD-speciﬁc environmental changes may
favour fungi at the expense of bacteria. These results were par-
ticularly observed in CD patients with ileal involvement.
Notably, CD patients without ileal involvement behave like UC
patients with decreased fungal biodiversity (see online supple-
mentary ﬁgure S5A, D) and only small changes in their ITS2/
16S biodiversity ratio (ﬁgure 2D). Decreases in fungal gut
microbiota have recently been observed in paediatric patients
with IBD.24 However, the number of patients analysed in that
study did not enable the authors to discriminate them according
to disease phenotype and thus precluded the elucidation of CD
patients’ speciﬁcities. The ileum is a major actor in intestinal
physiology, notably by producing antimicrobial peptides and
absorbing bile acids, two functions that are altered in ileal CD
and with a potential high impact on luminal bacteria and
fungi.25–28 These alterations in ileal CD could be involved in
the speciﬁc microbiota alterations observed.
In accordance with published data, the fungal faecal micro-
biota composition of both HS and patients with IBD were domi-
nated by fungi from the Ascomycota and the Basidiomycota
phyla.7 24 29 30 Ascomycota and Basidiomycota abundances
were strongly negatively correlated with each other and were
among the most important discriminative features between IBD
and HS microbiota as well as between IBD ﬂare and remission.
Logically, the Basidiomycota-to-Ascomycota abundance ratio
differed between patients with IBD and HS. Compared with
Figure 6 Imbalance trans-kingdom
network in IBD. Correlation network in
healthy subjects (A), Crohn’s disease
(B) and UC (C) generated using
Cytoscape. Each circle (node)
represents a microbial genus, its colour
represents the bacterial or fungal
phylum it belongs to and its size
represents the number of direct edges
that it has. The edge colour indicates
the magnitude of the distance
correlation; green indicates positive
correlation and red indicates negative
correlation (determined using
spearman test). Statistical signiﬁcance
was determined for all pairwise
comparisons; only signiﬁcant
correlations (p value <0.05 after false
discovery rate correction) are displayed.
Table 1 Ten most significant associations between IBD-associated fungi taxa and tested single-nucleotide polymorphisms (SNPs)
Outcome SNP Coded allele Gene Beta p Value
s__Malassezia sympodialis rs2078178 T Dectin-1 −0.264 0.003
s__Malassezia sympodialis rs4833095 T TLR1 0.198 0.019
p__Ascomycota rs5743611 G TLR1 0.545 0.036
s__Malassezia sympodialis rs3901533 T Dectin-1 −0.204 0.044
p__Basidiomycota rs5743611 G TLR1 −0.504 0.050
p__Ascomycota rs2287886 G DC-SIGN −0.197 0.058
s__Malassezia sympodialis rs5743618 T TLR1 −0.139 0.072
s__Saccharomyces cerevisiae rs10781499 G CARD9 0.193 0.072
s__Saccharomyces cerevisiae rs3775291 G TLR3 0.193 0.079
s__Malassezia sympodialis rs10841845 G Mincle −0.146 0.081
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HS, the ratio was high in patients with IBD in ﬂare (either UC
or CD) but was normal in remission, suggesting that this imbal-
ance between Basidiomycota and Ascomycota may be either
driven by inﬂammation or involved in the inﬂammatory
process.
We showed that S. cerevisiae represents a major component of
the normal fungal microbiota. Its decrease, conﬁrmed via real-
time qPCR, was independently associated with IBD (vs HS) and
with ﬂare (vs remission). S. cerevisiae has recently been shown
to reduce colitis induced by adherent-invasive E. coli, a bacteria
associated with ileal CD, in CEACAM6-expressing mice.31
S. boulardii, a probiotic yeast closely related to S. cerevisiae,32
has been shown to exhibit anti-inﬂammatory effects in several
colitis models7 as well as beneﬁcial effects in the prevention of
antibiotic-associated diarrhoea, acute diarrhoea, Clostridium dif-
ﬁcile infection and enteral feeding-related diarrhoea.33 Taken
together, these data suggest that S. cerevisiae could be poorly
adapted to an inﬂammatory environment and/or that it has an
anti-inﬂammatory potential. This raises the possibility of using
fungi in new therapeutic approaches in a manner similar to
what is currently being developed with several bacterial types.
The results obtained using an in vitro BMDC system suggest
that S. cerevisiae may exhibit regulatory effects on the host,
notably by inducing IL10 production. These results are in
accordance with another study reporting an increased expres-
sion of IL10 in the colons of mice receiving S. cerevisiae in a
colitis setting.34 Further experiments with S. cerevisiae and
other fungi, such as M. sympodialis, will be necessary to deter-
mine the role of these species in the gut and during intestinal
inﬂammation.
Although Candida was among the most abundant genera in
our studied population, it was not identiﬁed to be associated
with disease phenotype in the multivariate analysis. This may be
due to the high heterogeneity within the Candida genera and to
the difﬁculty in identifying fungi at the species level using our
sequencing approach. Indeed, the majority of the sequences
identiﬁed as belonging to the Candida genera were not assigned
to a speciﬁc species. Because several studies showed an increased
level of C. albicans in patients with IBD,7 24 30 we assessed its
abundance in the same samples using real-time qPCR. We con-
ﬁrmed a signiﬁcant increase of C. albicans abundance in patients
with IBD and particularly in ﬂare.
We herein identiﬁed a disease-speciﬁc fungal microbiota dys-
biosis with shifts in composition involving the two dominant
fungi phyla Ascomycota and Basidiomycota and several fungi
species including S. cerevisiae, M. sympodialis and C. albicans.
Although changes in the fungal microbiota of patients with IBD
could be connected with their altered dietary habits,35 these
shifts potentially also play a role in the inﬂammatory process.
Very little is known on the inﬂuence of M. sympodialis on intes-
tinal inﬂammation. Malassezia is a genus found on the skin of
mammalians and associated with numerous conditions from
dandruff to atopic eczema or pityriasis.36 Despite that
Malassezia clearly belongs to the human skin microbiota, species
of this genus have been frequently identiﬁed in the human gut
microbiota, suggesting possible colonisation of the gut.7 Indeed,
the genome of Malassezia shows the presence of genes coding
for secreted enzymes similar to the well-known human pathogen
C. albicans. Additionally, M. sympodialis is known to secrete
potent allergens that might increase local inﬂammation in
injured part of gut of patients with IBD.37 Recent data show
that M. sympodialis can activate mast cells to release cysteinyl
leukotrienes and enhance the mast cell IgE response, which
could contribute to inﬂammation.38 Moreover, we found
alterations of the fungi–bacteria diversity balance in CD that
might be explained by modiﬁed inter-kingdom interactions.
Fungi and bacteria coexist within the gut and may directly
interact. Commensal fungi and bacteria can be found together
in regions of the mouse gut.12 Antibiotics treatment in mice
leads to major fungi expansions that are then reduced following
antibiotic cessation,39 suggesting a balance between fungal and
bacterial microbiota. In addition to differences in the ITS2/16S
biodiversity ratio, we noted a disease-speciﬁc pattern for the
inter-kingdom network. We performed a correlation analysis
aiming at globally investigating the gut microbiota equilibrium.
It showed an imbalanced microbial network in patients with
IBD. In UC, the number and the intensity of the correlations
between fungi and bacteria were increased. This suggested
tighter interactions. On the other hand, the high ITS2/16S bio-
diversity ratio in CD associated with the weaker correlations
between fungi and bacteria suggested a disconnection between
the two kingdoms. Therefore, the role of the fungi microbiota
may differ according to UC versus CD pathogenesis. In UC, the
restricted biodiversity in bacteria and fungi is associated with
new inter-kingdom interactions that may be involved in the
inﬂammatory process. However, CD is characterised by dis-
rupted connections between bacterial and fungal microbiota.
This suggests that their respective effects on pathogenesis may
be independent. Further studies are needed to elucidate more
precisely the functional connections within and between king-
doms in the gut microbiota.
Finally, although our study was not of sufﬁcient power to stat-
istically demonstrate an association between genotype and
fungal microbiota, we identiﬁed some trends suggesting that
SNPs associated with IBD or IBD severity may inﬂuence fungal
microbiota dysbiosis.
CONCLUSION
In addition to elucidating bacterial dysbiosis, our study identi-
ﬁed a distinct fungal microbiota dysbiosis in IBD that is charac-
terised by alterations in biodiversity and composition.
Moreover, here, we unravel disease-speciﬁc inter-kingdom
network alterations in IBD, suggesting that, in addition to bac-
teria, fungi may also play a role in IBD pathogenesis. Identifying
the key players of these inter-kingdom interactions and under-
standing how they inﬂuence or are inﬂuenced by gut inﬂamma-
tion are further research avenues to pursue.
MATERIALS AND METHODS
Patients and samples collection
All patients were recruited at the Gastroenterology Department
of the Saint Antoine Hospital (Paris, France) and provided
informed consent. A diagnosis of IBD was deﬁned according to
clinical, radiological, endoscopic and histological criteria. None
of the study participants had taken antibiotics or used
colon-cleansing products for at least two months prior to enrol-
ment. Patient characteristics are presented in online supplemen-
tary table S1. Faecal samples were collected from 235 patients
with IBD and 38 HS. Whole stools were collected in sterile
boxes and immediately homogenised, and 0.2 g aliquots were
frozen at −80°C for further analysis.
Microbiota analysis in healthy subjects and patients with
IBD
Faecal samples were subjected to DNA extraction as previously
described.3 The DNA samples were then used for 16S and ITS2
gene sequencing and sequence analysis (see online supplemen-
tary materials and methods). For speciﬁc analysis of C. albicans
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and S. cerevisiae population, real-time quantitative PCR on the
faecal DNA was done (see online supplementary materials and
methods).
In vitro experiments on the response of dendritic cells to
S. cerevisiae and C. albicans
BMDCs were generated as described in the online supplemen-
tary materials and methods. BMDCs were stimulated with heat-
killed C. albicans or S. cerevisiae at an multiplicity of infection
(MOI) of 10 during 18 h and the cell culture supernatant was
used for ELISA analysis (see online supplementary materials and
methods).
Genotyping is described in the online supplementary materi-
als and methods.
Statistical analysis
GraphPad Prism V.6.0 (San Diego, California, USA) was used
for all analyses and graph preparation. For all graph data, the
results are expressed as mean±SEM, and statistical analyses
were performed using the two-tailed non-parametric Mann–
Whitney U test or Kruskal–Wallis test with Dunn’s multiple
comparison test. Statistical signiﬁcance of sample grouping for
beta diversity analysis was performed using Permanova method
(9999 permutations). Differences with a p value <0.05 were
considered signiﬁcant.
MaAsLin, a multivariate statistical framework, was used to
ﬁnd associations between clinical metadata and microbial com-
munity abundance.14
Correlation within microbial taxa abundance data was mea-
sured by correlation proposed by Szekely and Rizzo40 and
recommended by Simon and Tibshirani.41 It was used with
success in other microbiota data analysis42 as well as in human
genetic to identify gene network.43 It is scale free and allows
detecting non-linear relationship. The distance correlation is
bounded by 0 and 1 and is equal to 0 if there is independence
between variables. A statistical test is provided to assess for the
dependence between variables and is shown powerful and easy
to compute.41 In addition to the distance correlation, the
Spearman’s correlation sign was computed to describe heuristic-
ally the direction of association between microbial taxa. The dis-
tance correlation was computed under R-3.2.3 using the
package energy v1.6.2. The p values were corrected using
Benjamini and Hochberg to control false discovery rate.
Correlation networks were built using Cytoscape 3.1.1.
To investigate correlations between fungi taxa and genotype,
we performed a systematic association screening between the
four major independent taxa that were previously identiﬁed to
be associated with IBD (vs HS) or with ﬂare (vs remission)
(ﬁgure 3B, online supplementary ﬁgure S7B) and the 21
common candidate SNPs. All outcomes were standardised using
a rank normal transformation using the function rntransform
from the R package GenABEL ( http://cran.r-project.org/web/
packages/GenABEL/index.html). We used standard linear regres-
sion and adjusted all analyses for age, gender, smoking and
treatment.
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